The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: An association of CA IX with poor prognosis

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Nordfors, Kristiina ^a   Haapasalo, Joonas ^a   Korja, Miikka ^b,c   Niemelä, Anssi ^a   Laine, Jukka ^d   Parkkila, Anna Kaisa ^a   Pastorekova, Silvia ^e   Pastorek, Jaromir ^e   Waheed, Abdul ^f   Sly, William S ^f   Parkkila, Seppo ^g   Haapasalo, Hannu ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e INSTITUTE OF VIROLOGY   (Slovakia)

^f SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE XII; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; TUMOR ANTIGEN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; ENZYME LOCALIZATION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MEDULLOBLASTOMA; NEUROECTODERM TUMOR; NEWBORN; OLIGODENDROGLIOMA; PREDICTION; PRESCHOOL CHILD; PROGNOSIS; PROTEIN ANALYSIS; SCHOOL CHILD; TUMOR CELL; APOPTOSIS; BRAIN TUMOR; CEREBELLUM TUMOR; CHI SQUARE DISTRIBUTION; ENDOTHELIUM CELL; ENZYMOLOGY; FINLAND; INFANT; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK; TIME; TREATMENT OUTCOME; VASCULARIZATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; APOPTOSIS; CARBONIC ANHYDRASE II; CARBONIC ANHYDRASES; CEREBELLAR NEOPLASMS; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CYTOPLASM; ENDOTHELIAL CELLS; FEMALE; FINLAND; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; KAPLAN-MEIERS ESTIMATE; MALE; MEDULLOBLASTOMA; MIDDLE AGED; NEUROECTODERMAL TUMORS, PRIMITIVE; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; SUPRATENTORIAL NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77950886638     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-148     Document Type: Article

References (57)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. 2007, 132-146. IARC:Lyon.
2. Vandenberg SR, Herman MM, Rubinstein LJ. Embryonal central neuroepithelial tumors: current concepts and future challenges. Cancer Metastasis Rev 1987, 5(4):343-365. 10.1007/BF00055377, 2882864.
3. Shakhova O, Leung C, van Montfort E, Berns A, Marino S. Lack of Rb and p53 delays cerebellar development and predisposes to large cell anaplastic medulloblastoma through amplification of N-Myc and Ptch2. Cancer Res 2006, 66(10):5190-5200. 10.1158/0008-5472.CAN-05-3545, 16707443.
4. Sarkar C, Deb P, Sharma MC. Medulloblastomas: new directions in risk stratification. Neurol India 2006, 54(1):16-23. 10.4103/0028-3886.24696, 16679637.
5. Fogarty MP, Kessler JD, Wechsler-Reya RJ. Morphing into cancer: the role of developmental signaling pathways in brain tumor formation. J Neurobiol 2005, 64(4):458-475. 10.1002/neu.20166, 16041741.
6. Giangaspero F, Wellek S, Masuoka J, Gessi M, Kleihues P, Ohgaki H. Stratification of medulloblastoma on the basis of histopathological grading. Acta Neuropathol 2006, 112(1):5-12. 10.1007/s00401-006-0064-x, 16685513.
7. Rood BR, Macdonald TJ, Packer RJ. Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol 2004, 31(5):666-675. 10.1053/j.seminoncol.2004.07.009, 15497120.
8. McBride SM, Daganzo SM, Banerjee A, Gupta N, Lamborn KR, Prados MD, Berger MS, Wara WM, Haas-Kogan DA. Radiation is an important component of multimodality therapy for pediatric non-pineal supratentorial primitive neuroectodermal tumors. Int J Radiat Oncol Biol Phys 2008, 72(5):1319-1323.
9. Geyer JR, Sposto R, Jennings M, Boyett JM, Axtell RA, Breiger D, Broxson E, Donahue B, Finlay JL, Goldwein JW, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 2005, 23(30):7621-7631. 10.1200/JCO.2005.09.095, 16234523.
10. Pizer BL, Clifford SC. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. Br J Neurosurg 2009, 23(4):364-375. 10.1080/02688690903121807, 19637007.
11. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008, 7(2):168-181. 10.1038/nrd2467, 18167490.
12. Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004, 19(3):199-229. 10.1080/14756360410001689540, 15499993.
13. Sly WS, Hu PY. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 1995, 64:375-401. 10.1146/annurev.bi.64.070195.002111, 7574487.
14. Scozzafava A, Mastrolorenzo A, Supuran CT. Carbonic anhydrase inhibitors and activators and their use in therapy. Expert Opin Ther Patents 2006, 16(12):1627-1664.
15. Hilvo M, Tolvanen M, Clark A, Shen B, Shah GN, Waheed A, Halmi P, Hanninen M, Hamalainen JM, Vihinen M, et al. Characterization of CA XV, a new GPI-anchored form of carbonic anhydrase. Biochem J 2005, 392(Pt 1):83-92. 1317667, 16083424.
16. Haapasalo JA, Nordfors KM, Hilvo M, Rantala IJ, Soini Y, Parkkila AK, Pastorekova S, Pastorek J, Parkkila SM, Haapasalo HK. Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 2006, 12(2):473-477. 10.1158/1078-0432.CCR-05-0848, 16428489.
17. Haapasalo J, Nordfors K, Jarvela S, Bragge H, Rantala I, Parkkila AK, Haapasalo H, Parkkila S. Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy. Neuro Oncol 2007, 9(3):308-313. 10.1215/15228517-2007-001, 1907412, 17435181.
18. Kivela AJ, Kivela J, Saarnio J, Parkkila S. Carbonic anhydrases in normal gastrointestinal tract and gastrointestinal tumours. World J Gastroenterol 2005, 11(2):155-163.
19. Yoshiura K, Nakaoka T, Nishishita T, Sato K, Yamamoto A, Shimada S, Saida T, Kawakami Y, Takahashi TA, Fukuda H, et al. Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy. Clin Cancer Res 2005, 11(22):8201-8207. 10.1158/1078-0432.CCR-05-0816, 16299253.
20. Pastorekova S, Zavadova Z, Kostal M, Babusikova O, Zavada J. A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992, 187(2):620-626. 10.1016/0042-6822(92)90464-Z, 1312272.
21. Chrastina A, Zavada J, Parkkila S, Kaluz S, Kaluzova M, Rajcani J, Pastorek J, Pastorekova S. Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int J Cancer 2003, 105(6):873-881. 10.1002/ijc.11142, 12767076.
22. Pastorekova S, Parkkila S, Zavada J. Tumor-associated carbonic anhydrases and their clinical significance. Adv Clin Chem 2006, 42:167-216. full_text, 17131627.
23. Hilvo M, Baranauskiene L, Salzano AM, Scaloni A, Matulis D, Innocenti A, Scozzafava A, Monti SM, Di Fiore A, De Simone G, et al. Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem 2008, 283(41):27799-27809. 10.1074/jbc.M800938200, 18703501.
24. Tureci O, Sahin U, Vollmar E, Siemer S, Gottert E, Seitz G, Parkkila AK, Shah GN, Grubb JH, Pfreundschuh M, et al. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl Acad Sci USA 1998, 95(13):7608-7613. 10.1073/pnas.95.13.7608, 22698, 9636197.
25. Ivanov SV, Kuzmin I, Wei MH, Pack S, Geil L, Johnson BE, Stanbridge EJ, Lerman MI. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 1998, 95(21):12596-12601. 10.1073/pnas.95.21.12596, 22876, 9770531.
26. Kivela A, Parkkila S, Saarnio J, Karttunen TJ, Kivela J, Parkkila AK, Waheed A, Sly WS, Grubb JH, Shah G, et al. Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors. Am J Pathol 2000, 156(2):577-584. 1850052, 10666387.
27. Karhumaa P, Parkkila S, Tureci O, Waheed A, Grubb JH, Shah G, Parkkila A, Kaunisto K, Tapanainen J, Sly WS, et al. Identification of carbonic anhydrase XII as the membrane isozyme expressed in the normal human endometrial epithelium. Mol Hum Reprod 2000, 6(1):68-74. 10.1093/molehr/6.1.68, 10611263.
28. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000, 60(24):7075-7083.
29. Haapasalo J, Hilvo M, Nordfors K, Haapasalo H, Parkkila S, Hyrskyluoto A, Rantala I, Waheed A, Sly WS, Pastorekova S, et al. Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas. Neuro Oncol 2008, 10(2):131-138. 10.1215/15228517-2007-065, 2613815, 18322268.
30. Jarvela S, Parkkila S, Bragge H, Kahkonen M, Parkkila AK, Soini Y, Pastorekova S, Pastorek J, Haapasalo H. Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer 2008, 8:1. 10.1186/1471-2407-8-1, 2245965, 18173856.
31. Ihnatko R, Kubes M, Takacova M, Sedlakova O, Sedlak J, Pastorek J, Kopacek J, Pastorekova S. Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia. Int J Oncol 2006, 29(4):1025-1033.
32. Parkkila S, Rajaniemi H, Parkkila AK, Kivela J, Waheed A, Pastorekova S, Pastorek J, Sly WS. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci USA 2000, 97(5):2220-2224. 10.1073/pnas.040554897, 15781, 10688890.
33. Supuran CT. Indisulam: an anticancer sulfonamide in clinical development. Expert Opin Investig Drugs 2003, 12(2):283-287. 10.1517/13543784.12.2.283, 12556221.
34. Supuran CT, Briganti F, Tilli S, Chegwidden WR, Scozzafava A. Carbonic anhydrase inhibitors: sulfonamides as antitumor agents?. Bioorg Med Chem 2001, 9(3):703-714. 10.1016/S0968-0896(00)00288-1, 11310605.
35. Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol 1995, 13(1):112-123.
36. Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, Mulne L, Boyett J, D'Angio G, Wechsler-Jentzsch K, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 1994, 81(5):690-698. 10.3171/jns.1994.81.5.0690, 7931615.
37. Sallinen PK, Haapasalo HK, Visakorpi T, Helen PT, Rantala IS, Isola JJ, Helin HJ. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 1994, 174(4):275-282. 10.1002/path.1711740407, 7884589.
38. Parkkila AK, Parkkila S, Juvonen T, Rajaniemi H. Carbonic anhydrase isoenzymes II and I are present in the zona glomerulosa cells of the human adrenal gland. Histochemistry 1993, 99(1):37-41. 10.1007/BF00268018, 8468192.
39. Miettinen HE, Jarvinen TA, Kellner U, Kauraniemi P, Parwaresch R, Rantala I, Kalimo H, Paljarvi L, Isola J, Haapasalo H. High topoisomerase IIalpha expression associates with high proliferation rate and and poor prognosis in oligodendrogliomas. Neuropathol Appl Neurobiol 2000, 26(6):504-512. 10.1046/j.1365-2990.2000.00282.x, 11123716.
40. Haapasalo H, Hyytinen E, Sallinen P, Helin H, Kallioniemi OP, Isola J. c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. Br J Cancer 1996, 73(5):620-623. 2074346, 8605096.
41. Kallio JP, Hirvikoski P, Helin H, Luukkaala T, Tammela TL, Kellokumpu-Lehtinen P, Martikainen PM. Renal cell carcinoma MIB-1, Bax and Bcl-2 expression and prognosis. J Urol 2004, 172(6 Pt 1):2158-2161. 10.1097/01.ju.0000144334.97639.bf, 15538222.
42. Hynninen P, Vaskivuo L, Saarnio J, Haapasalo H, Kivela J, Pastorekova S, Pastorek J, Waheed A, Sly WS, Puistola U, et al. Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology 2006, 49(6):594-602. 10.1111/j.1365-2559.2006.02523.x, 17163844.
43. Kumpulainen T, Dahl D, Korhonen LK, Nystrom SH. Immunolabeling of carbonic anhydrase isoenzyme C and glial fibrillary acidic protein in paraffin-embedded tissue sections of human brain and retina. J Histochem Cytochem 1983, 31(7):879-886.
44. Kallio H, Pastorekova S, Pastorek J, Waheed A, Sly WS, Mannisto S, Heikinheimo M, Parkkila S. Expression of carbonic anhydrases IX and XII during mouse embryonic development. BMC Dev Biol 2006, 6:22. 10.1186/1471-213X-6-22, 1526727, 16719910.
45. Svastova E, Zilka N, Zat'ovicova M, Gibadulinova A, Ciampor F, Pastorek J, Pastorekova S. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp Cell Res 2003, 290(2):332-345. 10.1016/S0014-4827(03)00351-3, 14567991.
46. Zurawel RH, Chiappa SA, Allen C, Raffel C. Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res 1998, 58(5):896-899.
47. Chiche J, Ilc K, Laferriere J, Trottier E, Dayan F, Mazure NM, Brahimi-Horn MC, Pouyssegur J. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009, 69(1):358-368. 10.1158/0008-5472.CAN-08-2470, 19118021.
48. Diaz-Gonzalez JA, Russell J, Rouzaut A, Gil-Bazo I, Montuenga L. Targeting hypoxia and angiogenesis through HIF-1alpha inhibition. Cancer Biol Ther 2005, 4(10):1055-1062.
49. Proescholdt MA, Mayer C, Kubitza M, Schubert T, Liao SY, Stanbridge EJ, Ivanov S, Oldfield EH, Brawanski A, Merrill MJ. Expression of hypoxia-inducible carbonic anhydrases in brain tumors. Neuro Oncol 2005, 7(4):465-475. 10.1215/S1152851705000025, 1871734, 16212811.
50. Goethals L, Debucquoy A, Perneel C, Geboes K, Ectors N, De Schutter H, Penninckx F, McBride WH, Begg AC, Haustermans KM. Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. Int J Radiat Oncol Biol Phys 2006, 65(1):246-254.
51. Shin KH, Diaz-Gonzalez JA, Russell J, Chen Q, Burgman P, Li XF, Ling CC. Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. Cancer Biol Ther 2007, 6(1):70-75. 10.1158/1535-7163.MCT-06-0125, 17172824.
52. Patard JJ, Fergelot P, Karakiewicz PI, Klatte T, Trinh QD, Rioux-Leclercq N, Said JW, Belldegrun AS, Pantuck AJ. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 2008, 123(2):395-400. 10.1002/ijc.23496, 2721857, 18464292.
53. Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, Dohner K, Schlenk RF, Pollack JR, Dohner H, et al. Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood 2006, 108(13):4109-4117. 10.1182/blood-2006-01-023127, 16931630.
54. Alterio V, Hilvo M, Di Fiore A, Supuran CT, Pan P, Parkkila S, Scaloni A, Pastorek J, Pastorekova S, Pedone C, et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci USA 2009, 106(38):16233-16238. 10.1073/pnas.0908301106, 2752527, 19805286.
55. Haslam RH, Lamborn KR, Becker LE, Israel MA. Tumor cell apoptosis present at diagnosis may predict treatment outcome for patients with medulloblastoma. J Pediatr Hematol Oncol 1998, 20(6):520-527. 10.1097/00043426-199811000-00002, 9856671.
56. Nakasu S, Nakasu Y, Nioka H, Nakajima M, Handa J. bcl-2 protein expression in tumors of the central nervous system. Acta Neuropathol 1994, 88(6):520-526. 10.1007/BF00296488, 7879598.
57. Davis ID, Liu Z, Saunders W, Lee FT, Spirkoska V, Hopkins W, Smyth FE, Chong G, Papenfuss AT, Chappell B, et al. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immun 2007, 7:14.